| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/31/2005 | US20050070595 Complex of trioxane with iron compound |
| 03/31/2005 | US20050070591 Indole derivative |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease |
| 03/31/2005 | US20050070579 Performing crystallization by using an organic solvent selected from a ketone solvent, a nitrile solvent, and a mixture thereof, or a mixture of organic solvent and water; acetone or acetonitrile can be preferably used as the organic solvent |
| 03/31/2005 | US20050070575 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070568 Therapeutic acridone and acridine compounds |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070561 For example, 2-(3-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-phenylacetamide; use in the treatment of certain diseases, in particular to proliferative disease such as cancer |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070546 Tyrosine kinase inhibitors |
| 03/31/2005 | US20050070540 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070512 Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |
| 03/31/2005 | US20050070508 Modulators of receptor kinases such as VEGFR; treating cancer, benign hyperplasia; 6-[2-(1-Methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridin-7-yloxy]-naphthalene-1-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide for example |
| 03/31/2005 | US20050070494 Transforming growth factor-beta response element decoys and methods |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070487 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| 03/31/2005 | US20050070485 Phenylalanine derivatives |
| 03/31/2005 | US20050070474 Methods of treatment and compositions therefor |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference |
| 03/31/2005 | US20050070465 Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon |
| 03/31/2005 | US20050070463 membrane proteins associated with LPSs (lipopolysaccharides), for inducing maturation of dendritic cells; membrane fraction has a proteoglycan titer, represented by the sum of the contents of galactose and of proteins, between 1.2 g/l - 3.4 g/l for galactose and between 7.5 g/l - 14.9 g/l for proteins |
| 03/31/2005 | US20050070015 Methods of controlling proliferation of cancer cells and cell death |
| 03/31/2005 | US20050070005 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 03/31/2005 | US20050069989 Isoflavone-beta-D-glucan produced by agaricus blazei in the submerged liquid culture and method of producing same |
| 03/31/2005 | US20050069980 Transport protein for use as tool in altering in vivo pharmacokinetics of a pharmaceutical, toxic substance or xenobiotics by modulating an ability to transport acidic amino acids; antitumor agents |
| 03/31/2005 | US20050069964 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) |
| 03/31/2005 | US20050069960 Which induce proliferation of tumor-infiltrating lymphocytes without systemic toxicity associated with the administration of wild-type cytokines; drug screening/design |
| 03/31/2005 | US20050069946 Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer |
| 03/31/2005 | US20050069943 101 human secreted proteins |
| 03/31/2005 | US20050069888 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069871 Polypeptide-human zinc finger protein fpm315-17 and the polynucleotide encoding it |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069556 Serology display library; analyzing autologous tumor antigen; drug design; antitumor vaccine containing antigen |
| 03/31/2005 | US20050069547 Binding protein; therapy for bone tumors |
| 03/31/2005 | US20050069543 Antibody mixture; immunosuppressant ; antitumor agents |
| 03/31/2005 | US20050069535 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 03/31/2005 | US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 03/31/2005 | US20050069493 Administering a cobalamin linked with a diamino compound to a chelating group of a detectable metal, such as a radionuclide or paramagnetic metal ion |
| 03/31/2005 | DE10341307A1 Pharmarzeutischer Wirkstoff gegen Brustkrebs Pharmarzeutischer agent against breast cancer |
| 03/31/2005 | CA2808646A1 Thalidomide analogs |
| 03/31/2005 | CA2799282A1 Multi-arm polymer prodrugs |
| 03/31/2005 | CA2540138A1 Recombinant antibody against human insulin-like growth factor |
| 03/31/2005 | CA2540133A1 Drugs for treating cancer |
| 03/31/2005 | CA2539361A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| 03/31/2005 | CA2539359A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 03/31/2005 | CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 03/31/2005 | CA2539322A1 Kid3 and kid3 antibodies that bind thereto |
| 03/31/2005 | CA2539320A1 Use of chk1 inhibitors to control cell proliferation |
| 03/31/2005 | CA2539230A1 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 03/31/2005 | CA2539181A1 Modulation of eif4e expression |
| 03/31/2005 | CA2539172A1 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine |
| 03/31/2005 | CA2539067A1 Crystalline compound of 4'-demethyl-4'-phosphate-2",3"-bispentafluorophenoxyacetyl-4",6"-ethylidene-.beta.-d-epipodophyllotoxin glucoside either in its free form or solvated with ethanol |
| 03/31/2005 | CA2538864A1 Thalidomide analogs as tnf-alpha modulators |
| 03/31/2005 | CA2538855A1 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
| 03/31/2005 | CA2538760A1 Human .beta.-defensin secretion promoter |
| 03/31/2005 | CA2538729A1 Compound and method for treating androgen-independent prostate cancer |
| 03/31/2005 | CA2538523A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 03/31/2005 | CA2538284A1 Modulators of p-selectin glycoprotein ligand 1 |
| 03/31/2005 | CA2537731A1 Compositions useful as inhibitors of protein kinases |
| 03/31/2005 | CA2537094A1 Novel adenosine a3 receptor agonists |
| 03/31/2005 | CA2534959A1 Antibodies with altered effector functions |
| 03/31/2005 | CA2526862A1 Methods of diagnosing, prognosing and treating breast cancer |
| 03/30/2005 | EP1518864A2 Antibody against rhesus D |
| 03/30/2005 | EP1518854A1 Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines |
| 03/30/2005 | EP1518517A2 Drug-delivery endovascular stent and method for treating restenosis |
| 03/30/2005 | EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 03/30/2005 | EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained |
| 03/30/2005 | EP1517923A2 Compositions and methods for inhibiting microbial adhesion |
| 03/30/2005 | EP1517922A2 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures |
| 03/30/2005 | EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 03/30/2005 | EP1517911A1 Tumour-inhibiting platinum (ii) oxalate complexes |
| 03/30/2005 | EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
| 03/30/2005 | EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 03/30/2005 | EP1517898A1 Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases |
| 03/30/2005 | EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists |
| 03/30/2005 | EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 03/30/2005 | EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 03/30/2005 | EP1517701A2 Lewis y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| 03/30/2005 | EP1517700A2 Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| 03/30/2005 | EP1517699A1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 03/30/2005 | EP1517693A1 Pharmaceutical compositions |
| 03/30/2005 | EP1517691A1 Use of dopamine receptor agonists for the treatment of cutaneous tumors, warts, and scars |
| 03/30/2005 | EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 03/30/2005 | EP1517684A2 Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| 03/30/2005 | EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 03/30/2005 | EP1517606A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer |
| 03/30/2005 | EP1429648A4 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER |
| 03/30/2005 | EP1407047A4 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 03/30/2005 | EP1392341B1 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof |
| 03/30/2005 | EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders |